Loading...
Docoh
Log in Free sign up

SOPHiA Genetics (SOPH)

SOPHiA GENETICS is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally.

Company profile

Ticker
SOPH
Exchange
NASDAQ
Employees
Incorporated
Switzerland
Location
Switzerland
Fiscal year end
Dec 31
Sector
Manufacturing > Biological Product (except Diagnostic) Manufacturing
Industry (SIC)
Biological Products, (No Diagnostic Substances)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne ...
SEC CIK
0001840706
Corporate docs

SOPH stock data

News

From Benzinga Pro
Morgan Stanley Maintains Overweight on Sophia Genetics, Lowers Price Target to $13
10 Aug 22
Morgan Stanley analyst Tejas Savant maintains Sophia Genetics (NASDAQ:SOPH) with a Overweight and lowers the price target from $14 to $13.
Sophia Genetics: Q2 Earnings Insights
9 Aug 22
Sophia Genetics (NASDAQ:SOPH) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Sophia Genetics Q2 EPS $(0.31) Beats $(0.39) Estimate, Sales $11.70M Miss $11.95M Estimate
9 Aug 22
Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.39) by 20.51 percent. This is unchanged from the same period last year. The company reported
Earnings Scheduled For August 9, 2022
9 Aug 22
Why Is Ceragon Networks Surging By 19%? 41 Stocks Moving In Tuesday's Mid-Day Session
28 Jun 22

Press releases

From Benzinga Pro
SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2022
9 Aug 22
BOSTON and LAUSANNE, Switzerland, Aug. 09, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ:SOPH), a cloud-native software company in the healthcare space, today reported financial results for the second quarter
SOPHiA GENETICS to Host Investor Day on September 20, 2022, in New York City
4 Aug 22
BOSTON and LAUSANNE, Switzerland, Aug. 04, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ:SOPH), a cloud-native software company in the healthcare space, announced today it will host its first-ever Investor Day on
SOPHiA GENETICS to Participate in Canaccord Genuity 42nd Annual Growth Conference
29 Jul 22
BOSTON and LAUSANNE, Switzerland, July 29, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ:SOPH), a leader in data-driven medicine, announced today Chief Financial Officer, Ross Muken, will attend and be a panelist
SOPHiA GENETICS Publishes Results of 2022 Annual General Meeting
15 Jun 22
SOPHiA GENETICS Publishes Environmental, Social and Governance Impact Summary
15 Jun 22

Analyst ratings and price targets

Last 3 months
Morgan Stanley
Maintains
Overweight
$13.00
10 Aug 22

Calendar

15 Mar 22
16 Aug 22
31 Dec 22

Financial summary

Financial statements Chart SOPH financial data
Quarter (USD) Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Financial data from company earnings reports.

Institutional ownership, Q1 2022

SOPH institutional ownership history Ownership history
15.3% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 27 18 +50.0%
Opened positions 16 7 +128.6%
Closed positions 7 17 -58.8%
Increased positions 2 4 -50.0%
Reduced positions 5 4 +25.0%
13F shares Current Prev Q Change
Total value 205.12M 191.29M +7.2%
Total shares 23.76M 13.57M +75.2%
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners Shares Value Change
Generation Investment Management 6.79M $52.48M 0.0%
Balderton Capital VI, S.L.P. 3.36M $47.4M 0.0%
TROW T. Rowe Price 2.32M $17.93M NEW
Banque Pictet & Cie 2.1M $16.21M NEW
Partner Fund Management 2.01M $15.57M NEW
CS Credit Suisse 1.85M $14.33M NEW
Jennison Associates 1.5M $11.59M +4.0%
PFG Principal Financial Group Inc - Registered Shares 877.19K $6.78M -0.5%
Pura Vida Investments 829.93K $6.42M NEW
Pictet Asset Management 586.3K $4.53M -3.6%
Largest transactions Shares Bought/sold Change
TROW T. Rowe Price 2.32M +2.32M NEW
Banque Pictet & Cie 2.1M +2.1M NEW
Partner Fund Management 2.01M +2.01M NEW
CS Credit Suisse 1.85M +1.85M NEW
Pura Vida Investments 829.93K +829.93K NEW
Driehaus Capital Management 287.41K +287.41K NEW
Pictet & Cie 227.6K +227.6K NEW
RTW Investments 226.59K +226.59K NEW
Fred Alger Management 155.67K +155.67K NEW
Millennium Management 71.78K +71.78K NEW
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Koninklijke Philips • Illumina • PierianDx

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
From filing 20-F 2021 FY
Financial reports
20-F
2021 FY
Annual report (foreign)
15 Mar 22
Current reports
View all
6-K
Index to Consolidated Financial Statements
9 Aug 22
6-K
Current report (foreign)
15 Jun 22
6-K
Current report (foreign)
15 Jun 22
6-K
SOPHiA GENETICS Achieves CE-IVD Certification using its SOPHiA DDM™ Platform
14 Jun 22
6-K
Invitation to the Annual General Meeting
16 May 22
6-K
Index to Consolidated Financial Statements
10 May 22
6-K
SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directors
5 May 22
6-K
Current report (foreign)
26 Apr 22
6-K
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2021 Financial Results
15 Mar 22
6-K
Current report (foreign)
14 Mar 22
Registration and prospectus
F-3
Shelf registration (foreign)
8 Aug 22
424B4
Prospectus supplement with pricing info
23 Jul 21
S-8
Registration of securities for employees
23 Jul 21
S-8
Registration of securities for employees
23 Jul 21
8-A12B
Registration of securities on exchange
19 Jul 21
F-1/A
Registration statement (foreign) (amended)
19 Jul 21
F-1
Registration statement (foreign)
2 Jul 21
DRS
Draft registration statement
23 May 21
DRSLTR
Correspondence regarding draft registration statement
23 May 21
Proxies
No filings
Other
EFFECT
Notice of effectiveness
16 Aug 22
EFFECT
Notice of effectiveness
23 Jul 21
CERT
Certification of approval for exchange listing
22 Jul 21
CORRESP
Correspondence with SEC
19 Jul 21
CORRESP
Correspondence with SEC
19 Jul 21
CORRESP
Correspondence with SEC
6 Jul 21
CORRESP
Correspondence with SEC
1 Jul 21
UPLOAD
Letter from SEC
21 Jun 21
Ownership
SC 13G/A
SOPHiA GENETICS / GENERATION INVESTMENT MANAGEMENT ownership change
15 Feb 22
SC 13G
SOPHiA GENETICS / Coucke Marc ownership change
14 Feb 22
SC 13G
SOPHiA GENETICS / Balderton Capital VI, S.L.P. ownership change
10 Feb 22
SC 13G
SOPHiA GENETICS / GENERATION INVESTMENT MANAGEMENT ownership change
6 Jan 22

Patents

View all
Utility
Methods to compress, encrypt and retrieve genomic alignment data
19 Jul 22
A genomic data decoder may jointly compress and encrypt genomic data alignment information while preserving the privacy of sensitive genomic data elements at retrieval stage.
Utility
Methods for Detecting and Characterizing Microsatellite Instability with High Throughput Sequencing
14 Jul 22
The characterization, classification and reporting of MSI status of patient genomic samples may be provided by high throughput genomic analysis of a set of microsatellite marker loci.
Utility
Methods for Detecting Copy-number Variations In Next-generation Sequencing
28 Apr 22
Copy Number Variants (CNV) detection methods may integrate CNV detection into workflow for next generation sequencer (NGS) data processing, in parallel with SNP and INDEL variant calling.
Utility
Methods for Detecting Copy-number Variations In Next-generation Sequencing
31 Mar 22
Copy Number Variants (CNV) detection methods described herein may efficiently integrate CNV detection into the workflow for a next generation sequencer (NGS) data processing, in parallel with SNP and INDEL variant calling.
Utility
Methods for Identifying Chromosomal Spatial Instability Such As Homologous Repair Deficiency In Low Coverage Next- Generation Sequencing Data
17 Mar 22
A genomic data analyzer may be configured to detect and characterize, with a machine learning model such as a trained convolutional neural network, the presence of a genomic instability in a tumor sample.

Transcripts

2022 Q2
Earnings call transcript
13 Aug 22
2021 Q4
Earnings call transcript
15 Mar 22

Reddit threads

View all